Maze Therapeutics, Inc.'s (NASDAQ:MAZE) Lock-Up Period To Expire on July 30th

Maze Therapeutics' (NASDAQ:MAZE - Get Free Report) lock-up period is set to end on Wednesday, July 30th. Maze Therapeutics had issued 8,750,000 shares in its initial public offering on January 31st. The total size of the offering was $140,000,000 based on an initial share price of $16.00. After the end of Maze Therapeutics' lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Guggenheim reiterated a "buy" rating and set a $19.00 target price on shares of Maze Therapeutics in a report on Wednesday, April 2nd. Wedbush began coverage on shares of Maze Therapeutics in a research note on Tuesday, July 8th. They set an "outperform" rating and a $17.00 price objective for the company. Four research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $23.50.

Maze Therapeutics Trading Up 1.7%

Shares of NASDAQ:MAZE opened at $16.94 on Wednesday. The company has a 50 day moving average price of $12.33. Maze Therapeutics has a 1 year low of $6.71 and a 1 year high of $18.67.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($1.15) earnings per share for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.39).

Hedge Funds Weigh In On Maze Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Alphabet Inc. acquired a new position in shares of Maze Therapeutics during the first quarter valued at about $26,561,000. General Catalyst Group Management LLC acquired a new position in shares of Maze Therapeutics during the first quarter valued at about $11,405,000. Bessemer Group Inc. acquired a new position in shares of Maze Therapeutics during the first quarter valued at about $5,305,000. Hhlr Advisors LTD. acquired a new position in shares of Maze Therapeutics during the first quarter valued at about $5,037,000. Finally, Driehaus Capital Management LLC acquired a new position in shares of Maze Therapeutics during the first quarter valued at about $1,455,000.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.